Scioderm, a Raleigh, NC-based developer of novel dermatology therapeutics, completed a $16m Series A financing.
The round was led by Morgenthaler Ventures, with participation from Technology Partners. In conjunction with the funding, Dr. Chris Christoffersen (Partner of Morgenthaler Ventures) and Dr. Roger Quy (General Partner of Technology Partners), joined as members of Scioderm’s Board of Directors.
Led by Robert Ryan , Ph.D., Chief Executive Officer and Co-Founder, Scioderm is a clinical-stage pharmaceutical company focused on developing topical products to address critical medical needs in the treatment of chronic skin diseases.
The company intends to use the funds to advance a topical cream SD-101 into clinical development through registration for the treatment of the skin effects seen in patients across all EB subtypes, whose forms lead to scarring, disfigurement, disability and early death, usually before the age of 30.